ArticleJournal of arrhythmia2022
The efficacy and safety outcomes of cardiac resynchronization therapy in patients with heart failure in Thailand: Phramongkutklao experience.
Article in Journal of arrhythmia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac resynchronization therapy (CRT) is one of the crucial treatments in patients with symptomatic heart failure reduced ejection fraction. This study aimed to report the efficacy and safety of CRT implantation in treating patients with heart failure. The responders and related outcomes were also analyzed.
methodsMedical records of all patients with CRT implantation, because of heart failure treatment indication, in Phramongkutklao Hospital between 2008 and 2019 were reviewed. Free from death and heart failure hospitalization were analyzed as composited efficacy outcomes with survival analysis. Follow-up echocardiography was used to define a responder. The safety outcomes were reported using descriptive data. Cox-proportional hazard model analysis was used for the responder as a predictor of outcomes.
resultsA total of 152 patients underwent CRT implantation because of heart failure. 77.63% were male, the mean age of 65.9 ± 13.19 years, 59.85% were diagnosed with ischemic cardiomyopathy, mean LVEF of 22.69 ± 7.51%, and QRS duration of 147 ± 21 ms. Mean Follow-up was 41 months. The composited efficacy outcomes were 91.7%, 54.8%, and 35.4% at 1, 5, and 10 years, respectively. CRT-related complications were found in 12 patients (7.89%). 71.30% of patients who were responders had lower death or heart failure hospitalization when compared to non-responders (HR: 0.43, 95% CI: 0.24-0.78).
conclusionThe efficacy and safety in CRT treating patients in our center were consistent with the previous randomized and observational studies. The responder rate remained the same as in previous trials but was a strong predictor for better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.